Beta3 integrin expression in melanoma predicts subsequent metastasis
Previous studies have suggested that differential expression and/or activation of integrins facilitates metastatic progression in murine and human melanoma. While recent data show that the integrin alphavbeta3 is involved in tumor angiogenesis and that tumor growth may be abrogated by alphavbeta3 in...
Saved in:
Published in | The Journal of surgical research Vol. 63; no. 1; pp. 169 - 173 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
01.06.1996
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Previous studies have suggested that differential expression and/or activation of integrins facilitates metastatic progression in murine and human melanoma. While recent data show that the integrin alphavbeta3 is involved in tumor angiogenesis and that tumor growth may be abrogated by alphavbeta3 inhibitors in vitro, the clinical significance of beta3 integrin expression in human malignant melanoma is not known. To assess the prognostic value of beta3 integrin expression, we examined primary cutaneous melanomas from 160 patients followed for a mean of 98 months or until death. We quantified the percentage of tumor area stained with beta3 integrin Ab CD-61 using an image analyzer. beta3 integrin expression was detected in 107/160 primary melanomas (69%). beta3-integrin-positive (beta3+) tumors were thicker (mean 2.98 +/- 0.3 mm) than beta3-integrin-negative (beta3-) melanomas (mean 1.64 +/- 0.2 mm) (P = 0.002). Patients with beta3+ melanomas were more likely to relapse (57/107, 53%) and to die from disease (45/107, 42%) than those with beta3- tumors (6/53, 11%; and 4/53, 8%, respectively) (P < 0.001). Overall survival was greater for beta3- than for beta3+ patients (mean 102 +/- 9 vs 69 +/- 6 months) (P = 0.001). These data show that beta3 integrin expression in primary cutaneous melanoma predicts subsequent metastatic progression. Further study of beta3 integrins in the development of melanoma metastases may yield new therapeutic strategies, as well as prognostic information, for the treatment of this cancer. |
---|---|
AbstractList | Previous studies have suggested that differential expression and/or activation of integrins facilitates metastatic progression in murine and human melanoma. While recent data show that the integrin alphavbeta3 is involved in tumor angiogenesis and that tumor growth may be abrogated by alphavbeta3 inhibitors in vitro, the clinical significance of beta3 integrin expression in human malignant melanoma is not known. To assess the prognostic value of beta3 integrin expression, we examined primary cutaneous melanomas from 160 patients followed for a mean of 98 months or until death. We quantified the percentage of tumor area stained with beta3 integrin Ab CD-61 using an image analyzer. beta3 integrin expression was detected in 107/160 primary melanomas (69%). beta3-integrin-positive (beta3+) tumors were thicker (mean 2.98 +/- 0.3 mm) than beta3-integrin-negative (beta3-) melanomas (mean 1.64 +/- 0.2 mm) (P = 0.002). Patients with beta3+ melanomas were more likely to relapse (57/107, 53%) and to die from disease (45/107, 42%) than those with beta3- tumors (6/53, 11%; and 4/53, 8%, respectively) (P < 0.001). Overall survival was greater for beta3- than for beta3+ patients (mean 102 +/- 9 vs 69 +/- 6 months) (P = 0.001). These data show that beta3 integrin expression in primary cutaneous melanoma predicts subsequent metastatic progression. Further study of beta3 integrins in the development of melanoma metastases may yield new therapeutic strategies, as well as prognostic information, for the treatment of this cancer. Previous studies have suggested that differential expression and/or activation of integrins facilitates metastatic progression in murine and human melanoma. While recent data show that the integrin alphavbeta3 is involved in tumor angiogenesis and that tumor growth may be abrogated by alphavbeta3 inhibitors in vitro, the clinical significance of beta3 integrin expression in human malignant melanoma is not known. To assess the prognostic value of beta3 integrin expression, we examined primary cutaneous melanomas from 160 patients followed for a mean of 98 months or until death. We quantified the percentage of tumor area stained with beta3 integrin Ab CD-61 using an image analyzer. beta3 integrin expression was detected in 107/160 primary melanomas (69%). beta3-integrin-positive (beta3+) tumors were thicker (mean 2.98 +/- 0.3 mm) than beta3-integrin-negative (beta3-) melanomas (mean 1.64 +/- 0.2 mm) (P = 0.002). Patients with beta3+ melanomas were more likely to relapse (57/107, 53%) and to die from disease (45/107, 42%) than those with beta3- tumors (6/53, 11%; and 4/53, 8%, respectively) (P < 0.001). Overall survival was greater for beta3- than for beta3+ patients (mean 102 +/- 9 vs 69 +/- 6 months) (P = 0.001). These data show that beta3 integrin expression in primary cutaneous melanoma predicts subsequent metastatic progression. Further study of beta3 integrins in the development of melanoma metastases may yield new therapeutic strategies, as well as prognostic information, for the treatment of this cancer. |
Author | Ronan, S G Farolan, M Shilkaitis, A Wild, L Das Gupta, T K Hieken, T J |
Author_xml | – sequence: 1 givenname: T J surname: Hieken fullname: Hieken, T J organization: Department of Surgical Oncology, University of Illinois at Chicago 60612, USA – sequence: 2 givenname: M surname: Farolan fullname: Farolan, M – sequence: 3 givenname: S G surname: Ronan fullname: Ronan, S G – sequence: 4 givenname: A surname: Shilkaitis fullname: Shilkaitis, A – sequence: 5 givenname: L surname: Wild fullname: Wild, L – sequence: 6 givenname: T K surname: Das Gupta fullname: Das Gupta, T K |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/8661192$$D View this record in MEDLINE/PubMed |
BookMark | eNotj09LxDAQxYOsrLurH0HoyVshf5v2qKuuwoKXvZekmUikTWsnBf32BiwMDPPeY_i9PdnEMcIV2THaqLKutNiQHaWcl7Km8obsEb9ovhsttmRbVxVjDd-R5ydIRhQhJvicQyzgZ5oBMYwxa8UAvYnjYIosutAlLHCxCN8LxJTNZDBPwFty7U2PcLfuA7m8vlyOb-X54_R-fDyXkxK8tLQBbYSsJWWOOW-tVMxwraESzPuKQWWkdSA9VbXtOgDjlHbWso5a7bU4kIf_t9M8ZgRM7RCwgz4zwrhgq2tGpZI8B-_X4GIHcO00h8HMv-3aWvwBOB5Xvw |
ContentType | Journal Article |
DBID | CGR CUY CVF ECM EIF NPM 7X8 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
EISSN | 1095-8673 |
EndPage | 173 |
ExternalDocumentID | 8661192 |
Genre | Journal Article Comparative Study |
GroupedDBID | --- --K --M .1- .55 .FO .GJ .~1 0R~ 1B1 1P~ 1RT 1~. 1~5 29L 3O- 4.4 457 4CK 4G. 53G 5GY 5RE 5VS 7-5 71M 8P~ 9JM AABNK AACTN AAEDT AAEDW AAIAV AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AAXUO ABBQC ABFNM ABJNI ABLVK ABMAC ABMZM ABXDB ACDAQ ACGFS ACRLP ADBBV ADEZE ADFGL ADMUD AEBSH AEKER AENEX AEVXI AFCTW AFFNX AFKWA AFRHN AFTJW AFXIZ AGHFR AGUBO AGYEJ AHHHB AIEXJ AIKHN AITUG AJOXV AJRQY AJUYK AKRWK ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CAG CGR COF CS3 CUY CVF DM4 DU5 EBS ECM EFBJH EIF EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HEK HMK HMO HVGLF HZ~ IHE J1W J5H KOM LG5 M29 M41 MO0 N9A NPM O-L O9- OAUVE OK- OW- OZT P-8 P-9 P2P PC. Q38 R2- RIG ROL RPZ SAE SCC SDF SDG SDP SEL SES SEW SPCBC SSH SSZ T5K UHS WUQ X7M XPP Z5R ZA5 ZGI ZMT ZU3 ZXP ~G- 7X8 |
ID | FETCH-LOGICAL-p532-b09e7a348401d1dfbb451a277e631ff61e6a4bde4f058bcceead57dbb1c0b7f73 |
ISSN | 0022-4804 |
IngestDate | Sat Aug 17 02:45:12 EDT 2024 Thu May 23 23:01:11 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-p532-b09e7a348401d1dfbb451a277e631ff61e6a4bde4f058bcceead57dbb1c0b7f73 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
PMID | 8661192 |
PQID | 78104542 |
PQPubID | 23479 |
PageCount | 5 |
ParticipantIDs | proquest_miscellaneous_78104542 pubmed_primary_8661192 |
PublicationCentury | 1900 |
PublicationDate | 1996-Jun 19960601 |
PublicationDateYYYYMMDD | 1996-06-01 |
PublicationDate_xml | – month: 06 year: 1996 text: 1996-Jun |
PublicationDecade | 1990 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | The Journal of surgical research |
PublicationTitleAlternate | J Surg Res |
PublicationYear | 1996 |
SSID | ssj0002973 |
Score | 1.4963188 |
Snippet | Previous studies have suggested that differential expression and/or activation of integrins facilitates metastatic progression in murine and human melanoma.... |
SourceID | proquest pubmed |
SourceType | Aggregation Database Index Database |
StartPage | 169 |
SubjectTerms | Antigens, CD - analysis Antigens, CD - biosynthesis Disease-Free Survival Humans Immunohistochemistry Integrin beta3 Melanoma - immunology Melanoma - mortality Melanoma - pathology Multivariate Analysis Neoplasm Metastasis Platelet Membrane Glycoproteins - analysis Platelet Membrane Glycoproteins - biosynthesis Predictive Value of Tests Proportional Hazards Models Retrospective Studies Skin Neoplasms - immunology Skin Neoplasms - mortality Skin Neoplasms - pathology Survival Rate Time Factors |
Title | Beta3 integrin expression in melanoma predicts subsequent metastasis |
URI | https://www.ncbi.nlm.nih.gov/pubmed/8661192 https://search.proquest.com/docview/78104542 |
Volume | 63 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ3PS9xAFMeHKhS8SMVK1VZz6DVLZjOTyR7VKkuhXtyCt-XNLxp0s4vJXnro3-6bH3GWoqBewjJZQjKf8Hgzee_7JeQ7MNC4SoC8UEbnTHGegy1ELgvABUihlPAb-r-uq-lv9vOW3w4G47G7pJcj9ffZvpL3UMUx5Oq6ZN9A9umiOIC_kS8ekTAeX8X43PRQRsWHxqv1h6pWX724MPfQLhfgZAB042o2OgwSvnK6d8bRgHlh13Sb2WnqE_MZard-CHExKgI97RxPG3MXwtUsfVa6cqUjYTs1SWMvo_3xTfLwuvnT3N-Bk1JKW6k69uFVqTxqow2A1cE7eGRC9MR8La-r4E0yhNcYvzZfoxArafBo2eC0WnhQNeYMNDjk_aeFHc9ska2SuvrN0b9Uz-NMuAZpeHdfO-Rj_PvLiwefRMw-kd04t9lZQLlHPph2n_zwGLMBY5Yw4lg2YMwGjFnCmCWMn8ns6nJ2Mc2juUW-4qXzPZoYASXD9TXVVFspGacwFsJUJbW2oqYCJrVhtuC1VJjKgOZCS0lVIYUV5QHZbpet-UKyiiktx9Wk1sKwsZVgSiZ5oSyfQGGtOSSnw-PPMXa4D0LQmuW6m4uaOgXG8SE5CLMyXwWJk3mcuaOXThyTnfRSfCXb_cPafMPsrJcnnsojwhhAxw |
link.rule.ids | 315,786,790 |
linkProvider | Elsevier |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Beta3+integrin+expression+in+melanoma+predicts+subsequent+metastasis&rft.jtitle=The+Journal+of+surgical+research&rft.au=Hieken%2C+T+J&rft.au=Farolan%2C+M&rft.au=Ronan%2C+S+G&rft.au=Shilkaitis%2C+A&rft.date=1996-06-01&rft.issn=0022-4804&rft.eissn=1095-8673&rft.volume=63&rft.issue=1&rft.spage=169&rft_id=info%3Apmid%2F8661192&rft.externalDocID=8661192 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-4804&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-4804&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-4804&client=summon |